ImmuFact (eftilagimod alpha) / Immutep, EOC Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ImmuFact (eftilagimod alpha) / Immutep
AIPAC-002, NCT04252768: A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Withdrawn
1
24
NA
Eftilagimod Alpha, IMP321; efti, Paclitaxel
Immutep S.A.S.
Metastatic Breast Cancer
06/25
02/26
INSIGHT, NCT03252938: Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Hourglass Jan 2021 - Dec 2021 : Final data from INSIGHT-004 study in combination with Bavencio for solid tumors
Checkmark Presentation of data from INSIGHT-004 study in combination with Bavencio for advanced solid tumors at ASCO 2021
Jun 2021 - Jun 2021: Presentation of data from INSIGHT-004 study in combination with Bavencio for advanced solid tumors at ASCO 2021
Checkmark Data from INSIGHT 004 study in combination with avelumab for advanced solid tumors at ESMO 2020
Sep 2020 - Sep 2020: Data from INSIGHT 004 study in combination with avelumab for advanced solid tumors at ESMO 2020
More
Recruiting
1
110
Europe
IMP321, LAG-3Ig fusion protein, Avelumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Solid Tumors, Peritoneal Carcinomatosis
09/25
09/25

Download Options